TransCode Therapeutics, Inc. (RNAZ)
Nasdaq: RNAZ · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2020
Who runs TransCode Therapeutics, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedOfficers reporting now
2
of 4 people with a filing in the last fifteen months
Directors reporting now
2
9 people on the record since 2021
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Tattory John A | Interim CFO | Sep 2026 | Sep 21, 2026 | none |
| Fitzgerald Thomas A | Chief Financial Officer | Jul 2021 | Sep 11, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Czerepak Elizabeth | director | Dec 2025 | Dec 22, 2025 | none |
| Stover Jack E | director | Dec 2025 | Dec 22, 2025 | none |
Owners of more than 10% of a classsales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Ck Life Sciences Intl (Holdings) Inc | 10% owner | Aug 2026 | Aug 5, 2026 | none |
| Defj, LLC | 10% owner | Aug 2026 | Aug 5, 2026 | none |
Earlier names on the record6, newest filing first
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.